Redefining
Equine Health
A Breakthrough Solution for Laminitis — targeting the underlying cause of a disease the industry has managed, but never solved.
Mission statement
At Byrock Technologies our mission is to support veterinarians, owners and the equine industry in their task to improve the health of horses worldwide.
Quality
At Byrock Technologies, we uphold stringent standards in pharmaceutical development. Our flagship product, PTP-102, has successfully advanced through proof of concept studies, demonstrating significant potential to enhance equine health effectively and safely.
Teamwork
Our success is driven by collaborative efforts to fulfil our mission. Our multidisciplinary team combines deep scientific insight with extensive legal expertise to craft innovative solutions for equine health challenges.
Innovation
Driven by a mission to address critical gaps in equine healthcare, our team is at the forefront of pioneering treatments that merge scientific advancement with market demands. PTP-102 represents the first step in Byrock's journey to disrupt the equine healthcare market.
"PTP-100, by far gave the most promising results of a prophylactic or therapeutic treatment for this crippling equine disease."
Dr. Craig Reinemeyer
President, East Tennessee Clinical Research
Independent coverage
Selected third-party reporting on the published study. Not an endorsement.